Evidence map›Paper›PMID 18197482›Full record

ArticleClinical reviews in allergy & immunology2008

Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis.

Yves Renaudineau, Geogios N Dalekos, Paul Guéguen, Kalliopi Zachou, Pierre Youinou

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical reviews in allergy & immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Autoantibodies in the follow-up of autoimmune hepatitis.Journal of translational autoimmunity · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Autoantibody-negative autoimmune hepatitis.Digestive diseases and sciences · 2012
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Vasculitis: current status and future directions.Clinical reviews in allergy & immunology · 2008
    Article
  15. Cutting edge issues in autoimmunity.Clinical reviews in allergy & immunology · 2008
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Yves RenaudineauBrest University Medical School Hospital, Brest Cedex, France.
Geogios N Dalekos
Paul Guéguen
Kalliopi Zachou
Pierre Youinou
Centre Hospitalier Régional Universitaire de Brest · FRUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, we have observed that the association of anti-F-actin autoantibodies (Abs) with anti-alpha-actinin Abs (double reactivity) was correlated with liver disease activity in autoimmune hepatitis type 1 (AIH-1; Guéguen et al., J Clin Immunol 26:495-505, 2006). As anti-alpha-actinin Abs are also associated with anti-single-stranded (ss) DNA in 16 of 50 (32%) AIH-1 patients, compared with 16 of 401 (4.0%) liver disease control patients, we sought to characterize these Abs in AIH-1. When associated, anti-ssDNA Abs cross-react with anti-alpha-actinin Abs, but neither with anti-double-stranded DNA Abs nor with anti-F-actin Abs. Furthermore, anti-alpha-actinin Abs are associated with high-avidity anti-ssDNA Abs in AIH-1. In addition, double reactivity against alpha-actinin and ssDNA was correlated with clinical and histological activity of the disease and untreated AIH-1 patients.

Indexed as

ActininActinsAntibodies, AntinuclearAutoantibodiesAutoimmunityCross ReactionsDNA, Single-StrandedHepatitis, AutoimmuneHumansActininActinsAntibodies, AntinuclearAutoantibodiesDNA, Single-Stranded

Identifiers

PMID18197482
OpenAlexW2045199144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.